SA
Create Free Alerts
MPLTMPLTNASDAQ
Loading
OverviewIntelligenceChartsNews

Latest News

MapLight Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com

MapLight Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO and BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conferences: Event: Jefferies 2026 Biotech on the Beach Summit (Miami, FL) Date: Tuesday, March 10th Format: Hosting 1x1 meetings Event: Leerink 2026 Global Healthcare Conference (Miami, FL) Date: Wednesday, March 11th Format: Presenting and hosting 1x1 meetings Event: Stifel 2026 Virtual CNS Forum Date: Wednesday, March 18th Format: Presenting and hosting 1x1 meetings Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events & Presentations” page on the Investor section of the company's website at https://ir.maplightrx.com/news-events/events-presentations. About MapLight Therapeutics MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders.

Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Up After Insider Buying Activity
defenseworld.net

Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Up After Insider Buying Activity

Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) gapped up before the market opened on Monday following insider buying activity. The stock had previously closed at $17.88, but opened at $18.87. Maplight Therapeutics shares last traded at $19.93, with a volume of 101,257 shares trading hands. Specifically, Director George Pavlov bought 9,920 shares of Maplight

Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Down – Time to Sell?
defenseworld.net

Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Down – Time to Sell?

Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report)'s stock price gapped down before the market opened on Friday. The stock had previously closed at $16.80, but opened at $16.04. Maplight Therapeutics shares last traded at $16.37, with a volume of 6,739 shares traded. Analyst Ratings Changes Several brokerages have recently commented on MPLT. Leerink

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis
globenewswire.com

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis

SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M1/M4 muscarinic agonist, for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP).

SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
globenewswire.com

SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies

SAN FRANCISCO and BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- SandboxAQ and MapLight Therapeutics, Inc. (Nasdaq: MPLT) announced today that the companies have entered into a strategic collaboration to discover and develop potential first-in-class therapies targeting a novel G protein-coupled receptor (GPCR) for the treatment of central nervous system (CNS) disorders. Under the terms of the agreement, SandboxAQ received an upfront payment and will be eligible to receive additional preclinical, development, regulatory, and commercial milestone payments of up to $200 million in aggregate.

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
globenewswire.com

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026 Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer's disease psychosis expected in the second half of 2027 Raised $296.5 million in gross proceeds from initial public offering and concurrent private placement completed in October 2025 Cash, cash equivalents and short-term investments sufficient to fund operations through 2027 SAN FRANCISCO and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the third quarter of 2025 and highlighted recent progress and upcoming milestones. “2025 was a year of exceptional execution and acceleration for MapLight,” said Chris Kroeger, Chief Executive Officer of MapLight Therapeutics.

MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
globenewswire.com

MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN FRANCISCO and BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced the closing of its initial public offering of 16,962,500 shares of common stock at an initial public offering price of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 2,212,500 shares of common stock.

MapLight Therapeutics Announces Pricing of Initial Public Offering
globenewswire.com

MapLight Therapeutics Announces Pricing of Initial Public Offering

SAN FRANCISCO and BOSTON, Oct. 26, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced the pricing of its initial public offering of 14,750,000 shares of common stock at an initial public offering price of $17.00 per share. In addition, MapLight has granted the underwriters a 30-day option to purchase up to an additional 2,212,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

US IPO Weekly Recap: 5 Small IPOs Debut, As Government Shutdown Drags On
seekingalpha.com

US IPO Weekly Recap: 5 Small IPOs Debut, As Government Shutdown Drags On

Five small IPOs debuted and four SPACs listed this week as the government shutdown continues to complicate listings. Two sizable IPOs are scheduled for the week ahead, both of which launched after the government shutdown began. Street research is expected for six companies in the week ahead, and two lock-up periods will be expiring.

MapLight Therapeutics Starts $100 Million IPO Effort For CNS Treatments
seekingalpha.com

MapLight Therapeutics Starts $100 Million IPO Effort For CNS Treatments

MapLight Therapeutics is a clinical-stage biopharma focused on CNS disorders and has filed for a $100 million U.S. IPO to fund its pipeline. MPLT's lead drug, ML-07C-MA, targets schizophrenia and Alzheimer's Disease Psychosis, with Phase 2 topline results expected in late 2026 and 2027. The CNS treatment market is large and growing, but efficacy for MPLT's candidates remains unproven until further trial data is available.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance